Effectiveness Of The Quadrivalent HPV Vaccine Against Anal ≥HSILs In A Spanish Population Of HIV+ MSM Aged >26 Years

Carmen Hidalgo-Tenorio (chidalgo72@gmail.com)
Hospital Universitario Virgen de las Nieves

Jessica Ramirez-Taboada
Mohamed Omar-Mohamed
Antonio Sampedro
Miguel Angel Lopez-Ruz
Javier Lopez Hidalgo
Juan Pasquau

Research

Keywords: Quadrivalent HPV vaccine, anal high-grade squamous intraepithelial lesion (HSIL), human immunodeficiency virus (HIV), men who have sex with men (MSM), anal cancer.

DOI: https://doi.org/10.21203/rs.3.rs-42139/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Anal squamous cell carcinoma is the most frequent virus-related non-AIDS-defining neoplasia among HIV-infected individuals, especially MSM. The objectives of this study were: to analyze the effectiveness of the quadrivalent HPV (qHPV) vaccine to prevent anal ≥ high-grade squamous intraepithelial lesions (≥HSILs), external ano-genital lesions (EAGLs), and infection by qHPV vaccine genotypes in HIV+ MSM; and to study the immunogenicity of the vaccine and risk factors for ≥HSILs.

Methods: This study is nested within a randomized, double-blind, placebo-controlled trial of the qHPV vaccine, which enrolled participants between May 2012 and May 2014, with a 48-month follow-up. Vaccine or placebo was administered at 0, 2, and 6 months, and vaccine antibody titers were evaluated at 7, 12, 24, 36, and 48 months. Data were gathered at 12, 24, 36, and 48 months on sexual habits, CD4/CD8 cell counts, HIV viral load, and the results of cytology (Thin Prep® Pap Test), HPV PCR genotyping (Linear Array HPV Genotyping Test), and high-resolution anoscopy (Zeiss 150 fc® colposcope).

Results: The study included 129 patients, 66 (51.2%) in vaccine arm and 63 (48.4%) in placebo arm. The vaccine and placebo groups did not differ in ≥ HSILs (14.1 vs. 13.1%, respectively, p=0.98) or EAGL (14.3 vs. 13.6%, p=0.98) rates during follow-up; however, a protective effect against HPV 6 was observed during the first year of follow-up in the vaccine versus placebo group (7.5% vs. 23.4%; p=0.047). A between-arm difference (p=0.0001) in antibody formation was observed at 7 months (76.9% in vaccine arm vs. 30.2% in placebo arm), 12 months (68.1% vs. 26.5%), 24 months (75% vs. 32.5%), 36 months (90% vs. 24.4%), and 48 months (87.2% vs. 30%). Finally, receipt of the full vaccine 6 months earlier was a risk factor for ≥ HSIL (82.4% vs. 17.6%, OR 0.869 [95% CI 0.825-0.917]).

Conclusions: Vaccine and placebo arms did not significantly differ in ≥HSIL or EAGL rates or in protection against infection by HPV genotype vaccine except for HPV6 at 12 months after the first dose. A long-lasting immune response was observed in almost all of the vaccinated men. The main protective factor against ≥ HSIL was to have completed the vaccination regimen more than 6 months earlier.

Clinical trial registration: ISRCTN14732216 (http://www.isrctn.com/ISRCTN14732216)

Introduction

The incidence of anal squamous cell carcinoma (ASCC) is elevated in HIV-infected patients, especially in men who have sex with men (MSM) and in women with cervical disease (1), being much higher than in the general population [2]. ASCC progresses rapidly in the absence of medical treatment, and its early detection is of vital importance [3]. Chronic infection by human papillomavirus (HPV) is a risk factor for ASCC and for anal ≥ high-grade squamous intraepithelial lesions (HSILs) [4, 5].

Approaches to ASCC prevention include: programs for screening, diagnosis, treatment, and follow-up [4, 6]; the utilization of condoms to avoid HPV infection [7]; and the administration of HPV vaccine [8].
Various clinical trials have been published on the immunogenicity and/or effectiveness of the quadrivalent HPV (qHPV) vaccine in the anal-genital area of seronegative MSM. Comparison between MSM and men who have sex with women (MSW) found that the latter were at lower risk of external genital lesions (0.08/100 person-year at risk in MSW vs. 0.42/100 person-year at risk in MSM) [9], and more frequently generated antibodies (Abs) against vaccine genotypes (at month 36: Ab to HPV-6 in 89.5% of MSW vs. 80% of MSM; to HPV-11 in 94.3% vs. 89.1%; to HPV-16 in 98.3 vs. 93.9%; and to HPV-18 in 57.3 vs. 53.6%, respectively)[10]. Another non-randomized, open, one-arm trial in seronegative MSM reported an effectiveness rate of 50% against HSIL onset [11]. Various clinical trials have studied the immunogenicity and safety of the qHPV vaccine in HIV+ adult MSM. In one of these, virtually all patients developed antibodies against the qHPV vaccine genotypes [12]. However, the latest trial in adult HIV+ men and women, was interrupted due to a lack of effectiveness against HSIL onset [13].

In 2017, our group published the first results of this clinical trial on the immunogenicity and safety of the qHPV vaccine in VIH+ MSM, reporting that 70% of the vaccinated patients had Abs to HPV at seven months after the first dose [14]. The present study reports on the effectiveness of the vaccine in this population after a 48-month follow-up. The objectives were to evaluate the effectiveness of the qHPV vaccine against anal ≥ HSILs, external ano-genital lesions (EAGLs), and infection with HPV vaccine genotypes in VIH+ MSM and to determine the immunogenicity of the vaccine over four years and risk factors for ≥ HSILs.

**Patients And Methods**

Detailed information on the patients and methods used in our randomized, double-blind, placebo-controlled trial of the qHPV vaccine was previously published [14]. In summary, the sample comprised HIV-positive MSM ≥ 18 years of age not simultaneously infected by the four qHPV genotypes or both genotypes 16 and 18 who had normal high-resolution anoscopy (HRA) or an anal biopsy finding of condyloma and/or anal low-grade squamous intraepithelial lesion (LSIL) alone. Participants were enrolled between May 15 2012 and May 15 2014. The trial (ISRCTN14732216. DOI 10.1186/ISRCTN14732216) complied with the protocols of the Spanish Drugs and Health Products Agency [Agencia Española del Medicamento y Productos Sanitarios; AEMPS] and was approved by the local ethics committee. All data were coded to ensure anonymity, and all participants signed their fully informed consent. The protocol is available at [http://www.isrctn.com/ISRCTN14732216](http://www.isrctn.com/ISRCTN14732216).

In brief, using a methodology previously described in detail [14], data were collected at baseline and at 12, 24, 36, and 48 months on clinical-epidemiological variables and blood analysis results, including the HIV viral load (VL). Antibodies against the four qHPV vaccine genotypes were determined at month 7 (after the 3rd dose) and at 12, 24, 36, and 48 months.

Analyses were performed in the hospital microbiology department by a single microbiologist (A.S.). The HPVG ELISA commercial kit ([DIA.PRO](http://www.dia-pro.com), Milano, Italy), which measures antibodies against the major capsid protein (L1) of HPV types 6, 11, 16, 18, was applied according to the manufacturer’s instructions.
Blood samples were centrifuged and frozen at -20 °C until their analysis. Results are expressed as positive or negative.

The HRA, PCR, and cytology techniques employed are described in detail elsewhere [14]. HPV genotypes 16, 18, 26, 31, 33, 35, 39, 45, 51–53, 56, 58, 59, 66, 68, 73, and 82 were considered high risk (HR-HPV), and genotypes 6, 11, 34, 40, 42–44, 54, 55, 57, 61, 70–72, 81, 83, 84 and 89 low-risk (LR-HPV). HPV-18 virus species was classified as genotypes 39, 45, 59, 68 and HPV-16 species as genotypes 31, 33, 35, 52, 58, 67 [15]. Lesions were categorized according to the Bethesda cytology classification [16] as atypical squamous cells (ASCs), atypical squamous cells of undetermined significance (ASC-US), or atypical squamous cells – cannot rule out HSIL- (ASC-H). We adopted the histology classification of the Squamous Terminology (LAST) Standardization Project for HPV, categorizing lesions as LSIL (AIN1/condyloma), HSIL (AIN2, AIN3), or invasive carcinoma (ASCC) [17].

Participants were randomly assigned (1:1 ratio) to receive an 0.5 ml injection of quadrivalent HPV vaccine (Gardasil ©; Merck Research Laboratories) or placebo at day 1, month 2, and month 6 [14].

Sample size

The sample size was calculated to estimate a reduction of ≥ 50% after qHPV vaccination with a statistical power of 80% and level of significance of 5%, based on previous findings of pathological anal biopsy in 67.2% of HIV+ MSM, with 29.8% of these having HSIL (≥ AIN2) and 74.2% showing colonization by high-risk genotypes [18]. A sample size of 29 patients per arm was estimated, which was increased to 60 per arm to yield a statistical power of 98% [14].

Randomization

Participants were randomly assigned to the experimental or placebo group using a randomization sequence created with Epidat software (Epidat 4.2, 2016. Consellería de Sanidade, Xunta de Galicia, España; Organización Panamericana de la salud (OPS-OMS); Universidad CES, Colombia). Patients and researchers were blinded to the allocation of participants.

Statistical analysis

SPSS (version 19) and Stata Statistical Software Release 12 packages were used for statistical analyses. Means, standard deviation, medians, and percentiles were calculated for quantitative variables and absolute and relative frequencies for qualitative variables. The prevalence of HPV and ≥HSIL in anal mucosa was determined with 95% confidence interval (CI). The Kolmogorov-Smirnov test was applied to check the distribution of variables. Factors associated with infection by HR-HPV genotypes were analyzed using the Student t-test for quantitative variables with normal distribution and the Mann-Whitney test for those with non-normal distribution, and using the Pearson's chi-square test or Fisher test, as appropriate, for qualitative variables; the FDR correction was applied for multiple comparisons [19].
Multivariate Poisson regression analysis was then performed, including variables significant in bivariate analyses and others deemed clinically relevant. Variables were entered in the model by forward stepwise selection, setting the p-value of 0.05 or 0.10 to enter the model. P<0.05 was considered statistically significant in all tests.

Results

Patients enrolled in clinical trial

Out of 162 HIV + MSM patients undergoing screening from May 15 2012 through May 15 2014, 30 (18.5%) did not meet inclusion criteria and 3 (1.85%) withdrew their consent. The 129 patients in the final study sample were randomly assigned to the vaccine arm (n = 66, 51.2%) or placebo arm (n = 63, 48.4%). Among the 66 participants in the vaccine arm, 64 (96.9%) received all three doses of the vaccine and the remaining 2 participants only two doses, due to death from liver cirrhosis at 6 months post-enrolment and relocation to another city, respectively. Follow-up was completed by 110 (85.3%) participants, with a median of 48 months (P25: 36-P75 48), but not by 19 (14.7%), due to non-AIDS-defining disease in two cases (10.5%; lung cancer in 1 and decompensated liver cirrhosis in 1), with the remaining 17 (89.4%) being lost to follow-up (Fig. 1).

The mean age of the participants was 38.8 years, 69 (53.5%) had completed university studies, their sexual life had started a median of 19 years earlier, 40 (31%) had a history of AIDS, 119 (92.2%) were receiving antiretroviral treatment, and only 4 (3.3%) had virological failure. Table 1 lists the results for remaining variables, showing that patients in each arm were similar in age, social strata, educational level, sexual habits, consumption of toxic substances, other infections, and HIV-related data (virological and immunological status).
Table 1
Baseline demographics of HIV-positive MSM enrolled in the clinical trial

| Age, years; mean (± SD) | Total Cohort of HIV-MSM (n = 129) | HIV-MSM Vaccine (n = 66) | HIV-MSM Placebo (n = 63) | P* |
|-------------------------|-----------------------------------|--------------------------|---------------------------|----|
| 38.8 ((± 10.4) | 37.3 (± 10.6) | 40.5 (± 10.02) | 0.082 |
| Spanish nationality, n (%) | 123 (95.3) | 63 (95.5) | 60 (95.2) | 0.2 |
| University education, n (%) | 69 (53.5) | 34 (51.5) | 35 (55.5) | 0.56 |
| Partners in previous 12 months; median (IQR) | 1 (1-3.75) | 1 (1-3) | 1 (1-5) | 0.8 |
| Life-time partners; n, median (IQR) | 72.5 (20.5–300) | 50 (20–300) | 100 (45–350) | 0.041* |
| Years of sexual activity; median (IQR) | 19 (10–27) | 17 (9–24) | 21 (13–27) | 0.025* |
| Condom use, n (%) | 100 (77.5) | 53 (80.3) | 47 (74.6) | 0.4 |
| Perianal/genital condylomas at screening, n (%) | 40 (31) | 20 (30.3) | 20 (31.7) | 0.86 |
| History of condylomas, n (%) | 34 (26.4) | 19 (28.8) | 15 (23.8) | 0.52 |
| Duration of HIV; mean months (IQR) | 67.5 (31-123.5) | 58 (26–120) | 77 (37–138) | 0.2 |
| History of AIDS; n (%) | 40 (31) | 19 (28.8) | 21 (33.3) | 0.58 |
| CD4 mean nadir; cells/µL (± SD) | 335,12 (± 210.9) | 336(± 227.3) | 334.2(± 193.7) | 0.96 |
| CD4 mean; cells/µL (± SD) | 721.9 (± 258.8) | 733(± 252.7) | 710.4 (± 266.6) | 0.62 |
| CD8 mean; cells/µL (± SD) | 996.2 (± 422.04) | 999.9(± 463.6) | 992.2(± 374.9) | 0.98 |
| VL of HIV log10; copies/mL (± SD) | 3.72 (± 4.84) | 3.76 (± 4.5) | 3.67 (± 4.46) | 0.8 |
| VL < 50 copies/mL, n (%) | 106 (82.2) | 53 (80.3) | 53 (84.1) | 0.57 |

P*: p-value; p < 0.05

ART: antiretroviral therapy. VL: viral load; Ex-IDVA: ex-injection drug venous addiction.

* FDR correction for multiple comparisons showed that difference was not statistically significant.
|                                    | Total Cohort of HIV-MSM (n = 129) | HIV-MSM Vaccine (n = 66) | HIV-MSM Placebo (n = 63) | P* |
|------------------------------------|-----------------------------------|--------------------------|--------------------------|----|
| Virological failure, n (%)         | 4 (3.3)                           | 1 (1.5)                  | 3 (4.8)                  | 0.29 |
| ART, n (%)                         | 119 (92.2)                        | 60 (90.9)                | 59 (93.7)                | 0.745 |
| Median duration of ART; months (IQR) | 45 (17-101.25)                  | 42 (17–86)              | 43 (17–129)              | 0.42 |
| Number of lines of ART, median (IQR) | 1 (1–2)                           | 1 (1–2)                  | 1 (1–2)                  | 0.56 |
| Syphilis treated, n (%)            | 28 (21.7)                         | 16 (24.2)                | 12 (19.1)                | 0.47 |
| Other STD, n (%)                   | 23 (17.8)                         | 11 (16.6)                | 12 (19.1)                | 0.72 |
| Latent tuberculosis treated, n (%) | 15 (11.6)                         | 5 (7.6)                  | 10 (15.9)                | 0.14 |
| HCV, n (%)                         | 4 (3.1)                           | 2 (3)                    | 2 (3.2)                  | 1    |
| HBV, n (%)                         | 2 (1.6)                           | 2 (3)                    | 0 (0)                    | 0.49 |
| Smoking, packs/year, median (IQR)  | 1.9 (0-12.5)                      | 0.2 (0–1)                | 6.5 (0–18)               | 0.008* |
| Ex-smoking, n (%)                  | 23 (17.8)                         | 10 (15)                  | 13 (20.6)                | 0.42 |
| Ex-IVDA, n (%)                     | 1 (0.8)                           | 1 (1.5)                  | 0 (0)                    | 0.42 |
| Alcohol (standard units of alcohol; SUA) | 0.16(0–1)                     | 0 (0–1)                  | 0.4 (0-1.4)              | 0.15 |

**P*: p-value; p < 0.05

**ART**: antiretroviral therapy. **VL**: viral load; **Ex-IDVA**: ex-injection drug venous addiction.

* FDR correction for multiple comparisons showed that difference was not statistically significant.

With respect to anal infection by HPV genotype, 90 (73.8%) patients were infected with high-risk genotypes, 73 (59.8%) with low-risk genotypes, and 59 (48.4%) with both types of virus; 30 (24.6%) were infected with genotype 16, 19 (15.6%) with genotype 6, 15 (12.6%) with genotype 11, and 9 (7.4%) with genotype 18. Cytology results were normal in 53 (41.1%) patients and revealed LSIL in 60 (46.5%), HSIL in 5 (3.9%), and ASC-US in 11 (8.5%). Anal biopsy evidenced LSIL/AIN1 in 62 patients (48.1%) and was normal in 67 (51.9%). There was no between-group difference in genotype infection or in cytology or histological results (Table 2).
Table 2
Baseline HPV PCR, cytology, and HRA* results in the study population

| Variable                        | Total cohort of HIV-MSM (n = 122) | HIV-MSM Vaccine (n = 65) | HIV-MSM Placebo (n = 57) | P*   |
|---------------------------------|-----------------------------------|--------------------------|--------------------------|------|
| **PCR of HPV, n (%)**           |                                   |                          |                          |      |
| LR-HPV                          | 73 (59.8)                         | 39 (60)                  | 34 (59.6)                | 0.97 |
| HR-HPV                          | 90 (73.8)                         | 46 (70.8)                | 44 (77.2)                | 0.42 |
| LR and HR HPV, n (%)            | 59 (48.4)                         | 28 (43.1)                | 31 (54.4)                | 0.21 |
| **Number of HR-HPVs (IQR)**    | 1 (0–3)                           | 1 (0–2)                  | 2 (0–3)                  | 0.22 |
| **Number of LR-HPVs (IQR)**    | 1 (0–2)                           | 1 (0–2)                  | 1 (0–2)                  | 0.94 |
| **Genotypes, n (%)**            |                                   |                          |                          |      |
| HPV6                            | 19 (15.6)                         | 11 (16.9)                | 8 (14)                   | 0.66 |
| HPV11                           | 15 (12.6)                         | 8 (12.3)                 | 7 (12.3)                 | 0.99 |
| HPV16                           | 30 (24.6)                         | 15 (23.1)                | 15 (26.3)                | 0.68 |
| HPV16 species                   | 46 (37.8)                         | 22 (33.3)                | 24 (38.1)                | 0.49 |
| HPV18                           | 9 (7.4)                           | 4 (6.2)                  | 5 (8.8)                  | 0.58 |
| HPV18 species                   | 40 (32.8)                         | 18 (27.3)                | 22 (34.9)                | 0.35 |
| **Cytology, n (%)**             |                                   |                          |                          |      |
| Normal                          | 53 (41.1)                         | 26 (39.4)                | 27 (42.9)                | 0.69 |
| LSIL                            | 60 (46.5)                         | 34 (51.5)                | 26 (41.3)                | 0.24 |
| HSIL                            | 5 (3.9)                           | 1 (1.5)                  | 4 (6.3)                  | 0.21 |
| ASCUS                           | 11 (8.5)                           | 5 (7.6)                  | 6 (9.5)                  | 0.69 |
| **HRA, n (%)**                  |                                   |                          |                          |      |
| Normal                          | 67 (51.9)                         | 33 (50)                  | 29 (46)                  | 0.65 |
| LSIL(AIN1)                      | 62 (48.1)                         | 33 (50)                  | 34 (54)                  | 0.65 |

HRA*: high resolution anoscopy.
P**: p-value; p < 0.05

In relation to the prevalence of HSILs and ASCC during the follow-up of the global cohort, it was 10.5% (13/124) and 0.8% (1/124), respectively, at 12 months, in 0.95% (1/105) and 0% at 24 months, in 1.02%
(1/98) and 0% at 36 months, and in 1.075% (1/93) and 0%, respectively, at 48 months. The difference in ≥ HSIL prevalence between 12 months (11.3% [14 /124]) and 48 months. 1.07% [1/93] was statistically significant (p < 0.0001). There was also a decrease in the incidence of HSILs and ASCC, which was 104.8 × 1000 p-year and 806.45 × 100.000 p-year, respectively, at 12 months of follow-up, 62.8 × 1000 p-year and 448.4 × 100.000 p-year at 24 months, 48.54 × 1000 p-year and 323.64 × 100.000 p-year at 36 months; and 41.03 × 1000 p-year and 256.4 × 100.000 p-year at 48 months. The difference in the incidence of ≥ HSIL between 12 months and 48 months was also statistically significant (p < 0.0001). The only case of invasive perianal cancer was diagnosed in a patient who had been vaccinated 6 months earlier; it debuted with a hardened perianal lesion and a metastatic cervical lymph node in which high-risk genotype 33 was detected. Despite receiving chemotherapy and radiotherapy, he died at 12 months.

**Efficacy of qHPV vaccine**

The ≥ HSIL rate did not significantly differ between vaccinated and placebo groups during the 48-month follow-up (9 [14.1%] vs. 8 [13.1%], respectively, p = 0.87), finding no difference at 12 months (7/63 [11.1%] vs. placebo 7/61 [11.5%], respectively; p = 1); 24 months (0% vs. 2% [1/50], p = 0.472); 36 months (1.9% [1/53] vs. 0%, p = 1), or 48 months (2% [1/50] vs. 0%, p = 1).

During the 48-month follow-up, vaccine and placebo arms did not differ in the prevention of EAGLs/condylomas (9 [14.3%] vs. 8 [13.6%], respectively, p = 0.98), which were detected in 6.3% (4/63) of the vaccine group vs. 5.2% (3/58) of the placebo group at 12 months (p = 1), in 9.4% (5/53) vs. 5.9% (3/51), respectively, at 24 months (p = 0.72); in 8% (4/50) vs. 4.4% (2/45) at 36 months (p = 0.68); and in 6.4% (3/47) vs. 2.6% (1/38) at 48 months (p = 0.63). However, a significant decrease (p < 0.0001) was observed in the whole cohort between the prevalence of these lesions at study enrolment (31%, 40/129) and at the end of the follow-up (4.3%, 4/93).

No significant between-arm difference was found in the acquisition of the qHPV genotypes at 12 months with the exception of VPH-6, which was observed in 4 (7.5%) of the vaccine group vs. 11 (23.4%) of the placebo group (p = 0.047), detecting VPH 11 in 4 (7.7%) vs. 3 (6.3%), respectively (p = 1), VPH-16 in 12 (25.5%) vs. 10 (24.4%) (p = 1), and VPH-18 in 9 (15.8%) vs. 6 (11.8%) (p = 0.546); at 24 months, detecting VPH-6 in 4 (8.3%) vs. 2 (5.3%), respectively (p = 0.69), VPH-11 in 6 (13%) vs. 1 (2.3%) (p = 0.112), VPH-16 in 3 (9.4%) vs. 4 (11.1%) (p = 1), and VPH-18 in 3 (6.1%) vs. 1 (2.25) (p = 0.618); at 36 months, detecting VPH-6 in 1 (2.7%) vs. 3 (8.8%) (p = 0.34), VPH-11 in 2 (5.1%) vs. 0 (p = 0.49), VPH-16 in 4 (11.8%) vs. 1 (3.3%) (p = 0.36), and VPH-18 in 2 (4.7%) vs. 0 (p = 0.49); or at 48 months, detecting VPH-6 in 3 (9.1%) vs. 1 (3.7%) (p = 0.62), VPH-11 in 0 vs. 0; VPH-16 in 2 (6.7%) vs. 1 (3.8%) (p = 1), and VPH-18 in 2 (6.3%) vs. 0 (p = 0.493).

**Immunogenicity of qHPV vaccine**

Antibodies against qHPV vaccine genotypes were detected in 76.9% (50/65) of the vaccine group vs. 30.2% (19/63) of the placebo group at 7 months (p < 0.0001), in 68.1% (32/47) vs. 26.5% (13/50) at 12 months (p < 0.0001), in 75% (36/48) vs. 32.5% (13/40) at 24 months (p = 0.0001); in 90% (45/50) vs.
Factors related to ≥ HSIL onset

The sole factor significantly associated with the risk of anal ≥ HSIL onset during the two-year follow-up was the receipt of the last dose of the vaccine less than 6 months earlier in comparison to those vaccinated for a longer period (82.4% vs. 17.6% (OR 0.869 [95% CI, 0.825–0.917]). Results for the remaining study variables are exhibited in Table 3.
Table 3
Bivariate and multivariate analyses of factors associated with ≥ HSILs

| Factors                                                                 | HIV-MSM with ≥ HSIL (n = 17) | HIV-MSM without ≥ HSIL (n = 107) | P* | RR; (95% CI) |
|------------------------------------------------------------------------|-------------------------------|----------------------------------|----|--------------|
| q-HPV Vaccine, n(%)                                                    | 9 (52.9)                      | 55 (50.9)                        | 0.877 | 0.92          |
| Ab q-HPV Vaccine, n(%)                                                 | 9 (52.9)                      | 55 (50.9)                        | 0.877 | 0.92          |
| 7 months                                                               | 9 (52.9)                      | 55 (50.9)                        | 0.877 | 0.92          |
| 12 months                                                              | 8 (53.3)                      | 47 (45.1)                        | 0.56  | 0.2           |
| 24 months                                                              | 2 (100)                       | 54 (60.7)                        | 0.2   | 0.2           |
| 36 months                                                              | 1 (50)                        | 53 (61.6)                        | 0.391 | 0.41          |
| 48 months                                                              | 0                             | 3.46 (1.7–5.1)                   | 0.65  | 0.65          |
| Titers Ab 7 m, median (IQR)                                            | 2.21 (1.78–4.39)              | 2.39 (0–4.53)                    | 0.869 | 0.825–0.917   |
| Titers Ab 12 m, median (IQR)                                           | 3.48 (2.26–3.65)              |                                  | 0.869 | 0.289         |
| Interval between first dose and HSIL onset, IQR                        | 12 (12–12)                    | 48 (48–48)                       | 0.0001| 0.626         |
| Age; mean years (± SD)                                                 | 39 (10.98)                    | 38.54 (10.28)                    | 0.620 | 0.625         |
| Median HR-HPV, (IQR)                                                  | 1 (0–4)                       | 1 (0–3)                          | 0.454 | 0.552         |
| Median LR-HPV, (IQR)                                                  | 1 (0–2)                       | 1 (0–2)                          | 0.454 | 0.552         |
| University education, n (%)                                           | 8 (47.1)                      | 59 (54.6)                        | 0.626 | 0.69          |
| Retired, n(%)                                                         | 2 (11.8)                      | 11 (10.2)                        | 0.626 | 0.69          |
| Partners in previous 12 months; median (IQR)                          | 1 (0.5–2.5)                   | 1 (1–4)                          | 0.394 | 0.394         |
| Life-time partners; median (IQR)                                      | 100 (15–325)                  | 70 (22.75–300)                   | 0.988 | 0.988         |
| Time since start of sexual activity (years); median (IQR)             | 21 (11–28)                    | 18.5(10–27)                      | 0.552 | 0.552         |
| Condom use, n (%)                                                     | 13 (76.5)                     | 84 (77.8)                        | 1     | 0.289         |
| % condom use; median (IQR)                                            | 99 (5-100)                    | 100 (52.5–100)                   | 1     | 0.289         |
| Perianal/genital condyloma, n (%)                                      | 7 (41.2)                      | 32 (29.6)                        | 0.4   | 0.4           |
| History of condyloma, n (%)                                           | 2 (11.8)                      | 31 (28.7)                        | 0.235 | 0.235         |
| Smoking, n(%)                                                         | 10 (58.8)                     | 43 (38.9)                        | 0.12  | 0.12          |
| Smoking, packs/year; median (IQR)                                     | 2.7 (0–22)                    | 1.1 (0–12)                       | 0.267 | 0.267         |
| Ex-smoker, n (%)                                                      | 2 (11.8)                      | 20 (18.5)                        | 0.497 | 0.497         |
| Ex-IVDA, n (%)                                                        | 0                             | 1 (0.9)                          | 1     | 1             |
| Alcohol, consumer n(%)                                                | 6 (35.3)                      | 57 (52.8)                        | 0.18  | 0.18          |
| Alcohol (SDU), median, IQR                                            | 0 (0-1.5)                     | 0.2 (0–1)                        | 0.397 | 0.397         |
| Duration of HIV; mean (IQR)                                           | 90(52.5–214.5)                | 61.5 (29.25–123.5)               | 0.138 | 0.138         |
| CD4 mean nadir; cells/µL (± SD)                                       | 299.59(261.1)                 | 341.4 (205.9)                    | 0.456 | 0.456         |
| Naïve                                                                  | 1 (5.9)                       | 9 (8.3)                          | 1     | 1             |
| VL of HIV, log10(± SD)                                                | 2.54(3.12)                    | 3.79 (4.51)                      | 0.469 | 0.469         |
| VL < 50 copies/mL, n (%)                                              | 15 (88.2)                     | 87 (80.6)                        | 0.736 | 0.736         |
| CD4 mean; cells/µL, (± SD)                                            | 696.92(215)                   | 729.01 (268.4)                   | 0.64  | 0.64          |
| CD8 mean; cells/µL, (± SD)                                            | 1038.4(273.4)                 | 995.6 (446)                      | 0.71  | 0.71          |
| CD4/CD8                                                                | 0.74 (0.29)                   | 1.4 (5.85)                       | 0.634 | 0.634         |
| Previous AIDS diagnosis; n (%)                                        | 8 (47.1)                      | 31 (28.7)                        | 0.129 | 0.129         |
| Median duration of ART; months (IQR)                                  | 51 (26.5–74)                  | 55 (23–111)                      | 0.214 | 0.214         |
| Virological failure, n (%)                                            | 0                             | 4(4)                             | 0.418 | 0.418         |
| Syphilis, n (%)                                                       | 4 (23.5)                      | 22 (20.4)                        | 0.753 | 0.753         |
| Other STD, n (%)                                                      | 4 (23.5)                      | 22 (20.4)                        | 0.753 | 0.753         |
| HCV, n (%)                                                            | 0                             | 3                                | 1     | 1             |
| HBV, n (%)                                                            | 0                             | 2 (1.9)                          | 1     | 1             |
| AIN1 (1st HRA), n(%)                                                  | 9 (52.9)                      | 57 (52.8)                        | 0.99  | 0.99          |
| HR-HPV baseline, n (%)                                                | 13 (76.5)                     | 74 (73.3)                        | 1     | 1             |
| LR-HPV baseline, n (%)                                                | 11 (64.7)                     | 59 (58.4)                        | 0.625 | 0.625         |

P*: p-value; p < 0.05

q-HPV vaccine: quadrivalent human papillomavirus vaccine; Ab q-HPV Vaccine: antibody to q-HPV vaccine. HRA: high resolution anoscopy. SDU: standard drink unit.
| Factors                                      | HR and LR-HPV baseline, n(%) | HIV-MSM with ≥ HSIL (n=17) | HIV-MSM without ≥ HSIL (n=107) | P* | RR; (95% CI) |
|----------------------------------------------|------------------------------|-----------------------------|----------------------------------|----|--------------|
| HPV at baseline visit                        |                              |                             |                                   |    |              |
| HR and LR-HPV baseline, n(%)                 |                              |                             |                                   |    |              |
| HPV-6, n (%)                                 | 3 (17.6)                     | 16 (15.8)                   | 1                                |    |              |
| HPV-11, n (%)                                | 3 (17.6)                     | 12 (11.9)                   | 1                                |    |              |
| HPV-16, n (%)                                | 5 (29.4)                     | 24 (23.8)                   | 0.452                            |    |              |
| HPV-18, n (%)                                | 1 (5.9)                      | 7 (6.9)                     | 0.761                            |    |              |
| HPV-33, n (%)                                | 2 (11.8%)                    | 16 (15.8)                   | 1                                |    |              |
| HPV-35, n (%)                                | 0 (0)                        | 11 (10.9)                   | 1.0                              |    |              |
| HPV-39, n (%)                                | 1 (5.9)                      | 5 (5)                       | 0.362                            |    |              |
| HPV-45, n (%)                                | 2 (11.8)                     | 13 (12.9)                   | 1                                |    |              |
| HPV-51, n (%)                                | 0 (0)                        | 10 (9.9)                    | 1                                |    |              |
| HPV-53, n (%)                                | 1 (5.9)                      | 6 (5.9)                     | 0.354                            |    |              |
| HPV-55, n (%)                                | 1 (5.9)                      | 7 (6.9)                     | 1                                |    |              |
| HPV-58, n (%)                                | 3 (17.6)                     | 16 (15.8)                   | 1                                |    |              |
| HPV-59, n (%)                                | 1 (5.9)                      | 13 (12.9)                   | 0.689                            |    |              |
| HPV-66, n (%)                                | 0 (0)                        | 11 (10.9)                   | 0.362                            |    |              |
| HPV-68, n (%)                                | 4 (23.5)                     | 11 (10.9)                   | 0.228                            |    |              |
| HPV-73, n (%)                                | 0                            | 6 (5.9)                     | 0.591                            |    |              |
| HPV-82, n (%)                                |                              |                             |                                   |    |              |
| HPV 12 months after first dose               |                              |                             |                                   |    |              |
| HPV-6, n (%)                                 | 4 (23.5)                     | 22 (22.4)                   | 1                                |    |              |
| HPV-11, n (%)                                | 2 (11.8)                     | 13 (13.3)                   | 1                                |    |              |
| HPV-16, n (%)                                | 7 (41.2)                     | 37 (37.8)                   | 0.789                            |    |              |
| HPV-18, n (%)                                | 5 (29.4)                     | 11 (11.2)                   | 0.06                             |    |              |
| HPV-33, n (%)                                | 2 (11.8)                     | 6 (6.1)                     | 0.336                            |    |              |
| HPV-58, n (%)                                | 3 (17.6)                     | 10 (10.2)                   | 0.405                            |    |              |
| HPV-59, n (%)                                | 3 (17.6)                     | 6 (6.2)                     | 0.131                            |    |              |
| HPV-66, n (%)                                | 2 (11.8)                     | 9 (9.2)                     | 0.665                            |    |              |
| HPV-68, n (%)                                | 1 (5.9)                      | 4 (4.1)                     | 0.558                            |    |              |
| HPV-73, n (%)                                | 0                            | 5 (5.2)                     | 1                                |    |              |

P*: p-value; p < 0.05

**q-HPV vaccine**: quadrivalent human papillomavirus vaccine; **Ab q-HPV Vaccine**: antibody to q-HPV vaccine. HRA: high resolution anoscopy. SDU: standard drink unit.

**Discussion**

The patients in this cohort were aged > 26 years, had a very good virological/immunological status, and were under antiretroviral treatment, with 15.6, 12.6, 24.6, and 7.4% of them being previously infected with HPV genotypes 6, 11, 16, and 18, respectively. Around half of them had normal anal mucosa and around half had LISLs, while more than one-third were infected with subspecies of genotype 16 and around one-third with subspecies of genotype 18. Oncogenic virus 16 is the most frequently isolated HPV genotype in anal mucosa and has been related to EAGLs in both sexes [20, 21]. In particular, HIV positivity is one of the main risk factors for infection with high-risk HPV genotypes in MSM (22).
No statistically significant differences between vaccine and placebo arms were found in the onset of ≥HSILs or condylomas or in the acquisition of qHPV genotypes during the follow-up period, except for a lesser acquisition of genotype 6 at 12 months after the first dose in the vaccinated patients; however, all of these variables were reduced in the global cohort.

The HPV vaccine is recommended for individuals aged between 12 and 26 years in most countries, including Spain, based on expectations of a higher effectiveness in a non-virus-exposed population (23) and of a superior immune response in younger people (24). However, it has also proven effective in adult women with previous exposure to the qHPV vaccine genotypes (25). Moreover, the MAM trial found that the immune response of adult males aged 27 to 45 years was comparable to that of younger men and that the vaccine was effective against EAGLs and persistent HPV infection in men aged over 26 years (26). However, a trial on the effectiveness of quadrivalent HPV vaccine in seropositive adults was interrupted because there was no reduction in anal HSIL onset related to the vaccine genotypes, although there was a decrease in the rate of infection by these genotypes; this failure may be in part explained by the inclusion of adult HIV patients of both sexes in the trial [13]. The vaccine was found to reduce the development of EAGLs and anal HSILs in seronegative heterosexual men and MSM (9), with a slightly lesser reduction in the latter (11). The above data suggest that the vaccine should be offered to seropositive MSM of any age who are engaged in an active sexual life.

At one month after completing the vaccination regimen, around eight out of ten vaccinated patients had total Abs against the vaccine genotypes in comparison to three out of ten of those receiving placebo; furthermore, this difference was not only maintained during the follow-up but increased, and the percentage in the vaccine arm reached around 90%. These outcomes confirm the long-lasting immunity conferred by the qHPV vaccine in seropositive MSM, in agreement with previous observations (11, 26). One study of HIV + MSM found that 98% developed antibodies against the four vaccine genotypes (12), while another described a similar long-term immune response between seropositive and seronegative men, although Ab levels were lower in the former (27). At any rate, the clinical relevance of a low Ab concentration is unknown, and no concentration cutoff has been published that correlates with the vaccine's effectiveness against external lesions or anal, cervical, vulvar, or vaginal intraepithelial neoplasia (1, 13).

The main factor related to ≥ HSIL onset in our patient cohort was receipt of the last vaccine dose 6 months earlier, with only isolated cases being observed at 24, 38, and 48 months after completing the vaccine regimen. This may be explained by a slightly delayed immune response in these older adults, with antibodies being detected in a large proportion of vaccinated patients at 12 months after the first dose and in an even greater percentage at 24 months, remaining close to 90% until the end of the 48-month follow-up.

Limitations of the trial include the rigorous eligibility criteria, leading to the exclusion of screened patients for the presence of anal ≥ HSIL (14.2%) or for anal mucosal infection with both genotypes 16 and 18.
Further research is therefore necessary to evaluate the usefulness of the vaccine in patients with these characteristics.

**Conclusion**

This cohort of adult HIV + MSM evidenced a reduction in anal ≥ HSILs and EAGLs over the follow-up period, with no significant difference between those receiving quadrivalent HPV vaccine and those receiving placebo. However, receipt of the vaccine offered protection against the acquisition of genotype 6 during the first 12 months of follow-up. The main protective factor against ≥ HSIL onset in these HIV + MSM was to have completed the vaccination regimen more than 6 months earlier.

**Abbreviations**

qHPV vaccine: quadrivalent human papillomavirus vaccine; MSM: men who have sex with men; HR-HPV: high-risk human papillomavirus; HSIL: high-grade anal intraepithelial lesion; EAGL: external genital lesion; HIV: human immunodeficiency virus; LSIL: low-grade anal intra-epithelial lesion; ASCC: anal squamous cell carcinoma; HRA: high-resolution anoscopy; HM: heterosexual men; STD: sexually transmitted disease; AE: adverse event; VL: viral load; PCR: polymerase chain reaction; ART: anti-retroviral therapy; HBV: hepatitis B virus; HCV: hepatitis C virus

**Declarations**

**Ethics approval and consent to participate**

The project received approval from the hospital’s Ethics Committee (Institution Review Board) "Comité de Ética de la Investigación Biomédica de la Provincia de Granada (CEI-GRANADA)” University Hospital Virgen de las Nieves.

**Consent for publication**

The authors consent to publish this research in this journal.

**Availability of data and material**

Registration and protocol: ISRCTN14732216; available at http://www.isrctn.com/ISRCTN14732216).

**Competing interests**

The authors affirm that there were no conflicts of interest in the conduct of the study.

**Funding:** The study was supported by a grant (#PI-0615-2011) from the Public Health and Social Progress Foundation of the Government of Andalusia [La Fundación Pública Andaluza Progreso y Salud de la Consejería de Igualdad Salud y Política Social].
Authors’ Contributions

CH-T: conceptualization, methodology; investigation, writing (original draft preparation), and funding acquisition; JLH: resources, and investigation; AS: resources and investigation; MOM-G, JP, ML-R: supervision, visualization; JR-T and CG-A: software

Acknowledgements

The authors thank Manuela Expósito for her expert statistical help, Mercedes Álvarez-Romero for specialist nursing care and data collection, Marina Gutierrez-Ariza for expertise with the HPV PCR technology, and Rosario Javier-Martínez and Antonio Tapia-Gomez for patient management. They are especially grateful to the patients for their generous participation in this trial.

References

1. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611–622.

2. Ching-Hong PV, Palefsky JM. Natural History and Clinical Management of Anal Human Papillomavirus Disease in Men and Women Infected with Human Immunodeficiency Virus. Clinical Infectious Disease 2002; 35: 1127-34.

3. De Pokomandy A, Rouleau D, Ghittas G, Trottier H, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R, Franco EL, Coutlée F. (2011) HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 52: 1174-81

4. Hidalgo-Tenorio C, Gil-Anguita C, López Ruz MA, Omar M, López-Hidalgo J, Pasquau J. ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM. PLoS One. 2019;14: e0224183.

5. Salati SA, Al Kadi A. Anal cancer - a review. Int J Health Sci. 2012; 6: 206-30.

6. Tinmouth J, Peeva V, Amare H, Blitz S, Raboud J, Sano M, Steele L, Salit IE. Progression from Perianal High-Grade Anal Intraepithelial Neoplasia to Anal Cancer in HIV-Positive Men Who Have Sex with Men. Dis Colon Rectum 2016; 59: 836-42.

7. Lam JU, Rebolj M, Dugué PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014; 21: 38-50.

8. de Sanjosé S, Bruni L, Alemany L. HPV in genital cancers (at the exception of cervical cancer) and anal Press Med. 2014; 43(12P2): e423-e428.

9. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401–411.
10. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012; 19: 261-7.

11. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576–1585.

12. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246–1253.

13. Wilkin T, H. Chen, M.S. Cespedes, J.T. Leon-Cruz, C. Godfrey, E.Y. Chiao, et al., A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 Years or older: AIDS clinical trials group protocol A5298, Clin. Infect. Dis. 2018; 67: 1339–1346.

14. Hidalgo-Tenorio C, Ramírez-Taboada J, Gil-Anguita C, Esquivias J, Omar-Mohamed-Balgahata M, SamPedro A, Lopez-Ruz M, Pasquau J. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM). AIDS Res Ther. 2017 18; 14: 34.

15. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–527.

16. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114–2119.

17. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012; 16:205–242.

18. Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, Lopez de Hierro M, Pala P, Ramirez-Taboada J, Esquivias J et al. Antiretroviral therapy as a factor protective against anal dysplasia in HIV-infected males who have sex with men. PLoS One 2014; 27: e92376.

19. Benjamini Y, Hochberg Y. Series B. Methodological. Journal of the Royal Statistical Society. 1995; 57: 289-300.

20. Slama J, Sehnal B, Dusek L, Zima T, Cibula D. Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. Neoplasma. 2015; 62: 308-14.

21. Li Z1, Zhang H1, Li X1, Yang Y2, Xin H1, Li M1, Feng B1, Gao L Anal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi’an, China. Plos one 2015; 10: e0125120. doi: 10.1371/journal.pone.0125120. eCollection 2015

22. Alberts CJ, va Rooijen MS, Prins M, Pawlista M, Schim va der Loeff MF, Waterboer T. HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men. Sex Transm Dis 2015; 42: 129-34.
23. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan JT, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928 –1943

24. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–1943

25. X Castellsagué, N Muñoz, P Pitisuttithum, D Ferris, J Monsonego, K Ault, J Luna, E Myers, S Mallary, O M Bautista, J Bryan, S Vuocolo, R M Haupt, A Saah. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011; 105: 28–37.

26. Giuliano AR, Isaacs-Soriano K, Torres BN, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)-The MAM Study. Vaccine 2015; 33:5640–6.

27. Pinto LA, Wilkin TJ, Kemp TJ, Abrahamsen M, Isaacs-Soriano K, Pan Y, et al. Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. 2019; 37: 2502-2510.

Figures
Figure 1

Flow of patients through the study